Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CD33 for acute myeloid leukemia therapy.

BMC cancer - 3 Jan 2022

Liu Jingjing, Tong Jiayin, Yang Haiping

Abstract excerpt

BACKGROUND: The aim of this study was to analyze the level of CD33 expression in patients with newly diagnosed AML and determine its correlation with clinical characteristics. METHODS: Samples were collected for analysis from AML patients at diagnosis. We evaluated the level of CD33 expression by flow cytometry analysis of bone marrow. Chi-square or t- tests were used to assess the association between the high...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to fms-Like Tyrosine Kinase 3
Share to Kaplan-Meier Estimate

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Nucleophosmin

Share to Proportional Hazards Models

Share to Sialic Acid Binding Ig-like Lectin 3

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 34980040
DOI: 10.1186/s12885-021-09116-5
PMCID: PMC8722076

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CD33 for acute myeloid leukemia therapy.PMID 34980040Read ↗

Targeting CD33 for Acute Myeloid Leukemia TherapySemantic proximity Read ↗

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaSemantic proximity Read ↗

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Semantic proximity Read ↗

High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation.Semantic proximity Read ↗

Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemiaSemantic proximity Read ↗

Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.Semantic proximity Read ↗

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia TreatmentSemantic proximity Read ↗

Differences in CD33 Intensity Between Various Myeloid NeoplasmsSemantic proximity Read ↗

Gemtuzumab ozogamicin in acute myeloid leukemia.Semantic proximity Read ↗

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Semantic proximity Read ↗

CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agentsSemantic proximity Read ↗

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.